Search results
Biogen (NASDAQ:BIIB) Given New $342.00 Price Target at HSBC
ETF DAILY NEWS· 1 day agoBiogen (NASDAQ:BIIB – Free Report) had its price objective boosted by HSBC from $339.00 to $342.00 in a research note published on Friday morning, Benzinga reports. BTIG Research ...
Biogen Reports Progress on Corporate Responsibility Priorities
Morningstar· 6 days ago“As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the progress we have made to advance Biogen’s enduring legacy of pioneering innovative ...
US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Reuters via Yahoo News· 20 hours agoDonanemab has faced two separate regulatory delays in the United States, while a similar therapy by...
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 hour agoThese results were also shared at AACR. Moving to strategic partnerships. This quarter, we announced...
Analyst Report: Ionis Pharmaceuticals, Inc.
Morningstar Research via Yahoo Finance· 13 hours agoIts broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen ...
Biogen Inc Share Price | BVMF: BIIB34 Stock - Investing.com UK
Investing.com· 5 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
This midcap stock is rallying 16% after posting earnings and we told you to buy it By Investing.com
Investing.com· 5 days agoAlso part of our list of picks for May, Apple (NASDAQ:AAPL) stock jumped 7% in post-market trading...
Eli Lilly Alzheimer’s drug gets FDA panel date after approval delay
The Hill via AOL· 18 hours agoAn outside panel of advisers to the Food and Drug Administration (FDA) will meet next month to...
BXP, Biotech Company Spar Over Kendall Square Site
The Real Deal· 6 days agoBrammer Bio filed a lawsuit last week against Boston Properties and Turner Construction over work being done in Cambridge’s Kendall Square, the Boston...
Medicare Says It Expects To Spend $3.5 Billion In 2025 On Alzheimer’s Drug Leqembi, But This Is...
Forbes· 5 days agoSkepticism may be warranted when the Centers for Medicare and Medicaid Services’ Office of the...
